Medicus Pharma (NASDAQ:MDCX) Earns "Buy" Rating from D. Boral Capital

Medicus Pharma (NASDAQ:MDCX - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at D. Boral Capital in a research note issued on Monday,Benzinga reports. They presently have a $14.00 target price on the stock. D. Boral Capital's price objective would indicate a potential upside of 227.87% from the stock's previous close.

Separately, D Boral Capital raised shares of Medicus Pharma to a "strong-buy" rating in a research report on Monday, April 14th.

Medicus Pharma Stock Performance

MDCX traded up $0.32 on Monday, reaching $4.27. 34,283 shares of the company's stock were exchanged, compared to its average volume of 51,430. Medicus Pharma has a twelve month low of $1.80 and a twelve month high of $6.00. The company's 50 day simple moving average is $3.58.

Medicus Pharma (NASDAQ:MDCX - Get Free Report) last issued its earnings results on Friday, March 28th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.14. On average, sell-side analysts predict that Medicus Pharma will post -1.14 earnings per share for the current year.

Hedge Funds Weigh In On Medicus Pharma

An institutional investor recently bought a new position in Medicus Pharma stock. Interchange Capital Partners LLC purchased a new position in Medicus Pharma Ltd. (NASDAQ:MDCX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,457,165 shares of the company's stock, valued at approximately $3,628,000. Medicus Pharma comprises about 1.3% of Interchange Capital Partners LLC's holdings, making the stock its 15th biggest position. Interchange Capital Partners LLC owned approximately 13.43% of Medicus Pharma as of its most recent filing with the Securities and Exchange Commission.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.